Innate Pharma S.A. (NASDAQ: IPHA) Overview: A Biotech Innovator in Oncology
Innate Pharma(US:IPHA) Financial Modeling Prepยท2025-11-13 02:00The average price target for Innate Pharma S.A. (NASDAQ: IPHA) has increased from $3.5 to $5 in the last quarter, indicating a positive outlook from analysts.A recent hammer chart pattern suggests potential for a trend reversal, signaling possible support after a decline.Despite the optimistic trend, analysts from Leerink Partners maintain a conservative price target of $2, highlighting varied perspectives on the stock's future performance.Innate Pharma S.A. (NASDAQ: IPHA) is a leading biotechnology company ...